^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    20h
    International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (ACTRN12624000532505)
    P3, N=900, Recruiting, University of Birmingham | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    EWSR1 (EWS RNA Binding Protein 1)
    |
    doxorubicin hydrochloride • cyclophosphamide • Stivarga (regorafenib)
    1d
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=36, Recruiting, Changhai Hospital | N=12 --> 36 | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • KN5501
    1d
    Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, C17 Council
    New P1 trial
    |
    cisplatin • carboplatin • temozolomide • tamoxifen • cytarabine • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • thiotepa • Neupogen (filgrastim) • celecoxib oral
    1d
    CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV
    2d
    Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    dasatinib • cyclophosphamide • fludarabine IV • Carvykti (ciltacabtagene autoleucel)
    2d
    NCI-2018-01752: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=68, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan • methotrexate IV
    2d
    Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=59, Suspended, Henan Cancer Hospital | Recruiting --> Suspended | Trial primary completion date: Dec 2023 --> Nov 2024
    Trial suspension • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD79B (CD79b Molecule) • CD79A (CD79a Molecule)
    |
    carboplatin • Rituxan (rituximab) • cytarabine • cyclophosphamide • oxaliplatin • Brukinsa (zanubrutinib) • epirubicin • vincristine • prednisone
    2d
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=114, Recruiting, Kite, A Gilead Company | Trial primary completion date: Jul 2026 --> May 2027 | Trial completion date: Jul 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    2d
    A Blood Stem Cell Transplant for Sickle Cell Disease (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Mar 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • pentostatin
    2d
    R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=60, Completed, Henan Cancer Hospital | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Apr 2025
    Trial completion • Trial completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • vincristine • prednisone
    5d
    CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Chinese PLA General Hospital
    New P1/2 trial
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • HypoSti.CAR-HER2 T
    5d
    OLYMPIA-3: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=904, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Sep 2028 --> Apr 2029 | Trial primary completion date: Sep 2028 --> Mar 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Ordspono (odronextamab)
    6d
    Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Ruijin Hospital
    New trial
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel)
    6d
    AREN2231: A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) (clinicaltrials.gov)
    P3, N=1656, Recruiting, Children's Oncology Group | Initiation date: Dec 2025 --> Apr 2025
    Trial initiation date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • dactinomycin
    6d
    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=9, Terminated, Fred Hutchinson Cancer Center | Trial completion date: Sep 2025 --> Jan 2025 | Active, not recruiting --> Terminated; Study terminated due to end of funding.
    Trial completion date • Trial termination
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ
    6d
    LauT1: NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma (clinicaltrials.gov)
    P1, N=9, Recruiting, Centre Hospitalier Universitaire Vaudois | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV
    8d
    ShenJiaoLingCao Decoction ameliorates cyclophosphamide-induced splenic injury and immunosuppression via the inhibition of MEK/ERK signaling pathway activity and modulation of amino acid metabolism. (PubMed, J Ethnopharmacol)
    In the present study, we found that SJLCD has satisfactory immunomodulatory activity, which may be achieved by affecting the MEK/ERK signaling pathway and amino acid metabolism of the body.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • MAPK1 (Mitogen-activated protein kinase 1) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta)
    |
    cyclophosphamide
    8d
    Network-based pharmacological and experimentally validated study on the therapeutic effects and mechanisms of Polygonatum Rhizoma Ginseng Formula in immunocompromised mice. (PubMed, J Ethnopharmacol)
    HJRS effectively improved immune function in CTX-induced immunocompromised mice. Its mechanism of action may be associated with the regulation of intestinal microbiota dysbiosis, activation of the intestinal "SCFA-GPR41" pathway, and modulation of the downstream MAPK signaling pathway.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TNFA (Tumor Necrosis Factor-Alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • CD4 (CD4 Molecule)
    |
    cyclophosphamide
    8d
    PACIFICO: A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients (clinicaltrials.gov)
    P3, N=680, Completed, University of Liverpool | Unknown status --> Completed
    Trial completion
    |
    Rituxan (rituximab) • cyclophosphamide • vincristine • fludarabine IV
    8d
    Delayed T cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults. (PubMed, Blood Adv)
    Patients (median age 51, range 2-75) were categorized into four groups based on GVHD prophylaxis: ex-vivo T cell depletion (TCD/CD34), post-transplant cyclophosphamide (PTCy), calcineurin-inhibitor alone (CNI) or with anti-thymocyte globulin (CNI+ATG)...No clinical associations for CD4 counts were identifiable in pediatric patients. These findings underscore the importance of tailoring transplant strategies for adults to optimize immune recovery and improve patient outcomes.
    Journal
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide
    9d
    A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
    |
    TP53 mutation
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    9d
    Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma (clinicaltrials.gov)
    P2, N=92, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial
    |
    cisplatin • cyclophosphamide • arsenic trioxide
    9d
    Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (clinicaltrials.gov)
    P1, N=30, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2025 --> Jun 2027 | Trial completion date: Dec 2025 --> Jun 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD4 (CD4 Molecule) • CD2 (CD2 Molecule)
    |
    lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
    9d
    Autologous Stem Cell Transplant in Multiple Sclerosis (ACTRN12622000536763)
    P2, N=60, Recruiting, St Vincent's Hospital, Sydney | N=30 --> 60
    Enrollment change
    |
    cytarabine • cyclophosphamide • carmustine • methylprednisolone sodium succinate
    9d
    A Phase II dose escalation study of cyclophosphamide in haematopoietic stem cell transplantation in severe systemic sclerosis patients unfit for standard dose cyclophosphamide. (ACTRN12617000216314)
    P2, N=15, Active, not recruiting, St Vincent's Hospital Sydney | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide
    9d
    Ewing sarcoma of the rib with a rare PTEN mutation. (PubMed, Cancer Genet)
    PTEN mutations in ES, although rare, may result in a higher likelihood of chemotherapy resistance and poor prognosis. Clinical studies targeting specific molecular traits of these tumors, such as PTEN inactivation, could help improve outcomes in selected cases.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • EWSR1 (EWS RNA Binding Protein 1)
    |
    PTEN mutation
    |
    doxorubicin hydrochloride • Cabometyx (cabozantinib tablet) • cyclophosphamide • ifosfamide • etoposide IV • vincristine
    9d
    Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (clinicaltrials.gov)
    P2/3, N=790, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Mar 2028 --> Sep 2028
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    dasatinib • cytarabine • bortezomib • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • daunorubicin • Zolinza (vorinostat) • clofarabine • idarubicin hydrochloride • Oncaspar liquid (pegaspargase) • nelarabine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Purixan (mercaptopurine oral suspension) • prednisolone
    9d
    NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=16, Terminated, M.D. Anderson Cancer Center | N=60 --> 16
    Enrollment change
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin)
    9d
    Severe infection risk in triple and quadruple therapy for anti-MDA5 antibody-positive dermatomyositis. (PubMed, Clin Rheumatol)
    While both TCT and QCT have infection, the QCT group may be at a higher risk, hence highlighting the need for vigilance and adequate prophylaxis.
    Journal
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    cyclophosphamide
    9d
    EPCORE CLL-1: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (clinicaltrials.gov)
    P1/2, N=424, Recruiting, Genmab | N=304 --> 424
    Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    9d
    A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE) (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, ITB-Med LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV
    9d
    DALY II USA/ MB-CART2019.1 for DLBCL (clinicaltrials.gov)
    P2, N=248, Recruiting, Miltenyi Biomedicine GmbH | N=110 --> 248 | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • bendamustine • fludarabine IV • zamtocabtagene autoleucel (MB-CART2019.1)
    11d
    Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, UTC Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV
    11d
    A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cyclophosphamide • CAR.70/IL15-transduced CB-NK cells
    11d
    MPCT-012L: Study of LYL314 in Aggressive Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=270, Recruiting, Lyell Immunopharma, Inc. | N=150 --> 270 | Trial completion date: Dec 2029 --> Jan 2028 | Trial primary completion date: Jun 2025 --> Aug 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • fludarabine IV • rondecabtagene autoleucel (LYL314)
    11d
    Protective effects of Moringa oleifera leaf extract against cyclophosphamide-induced ovarian dysfunction and follicular loss in rats. (PubMed, Tissue Cell)
    Pretreatment with M. oleifera successfully mitigated CP-induced oxidative and inflammatory changes, as well as ovarian tissue damage, but failed to reverse serum hormonal imbalances. These findings demonstrate the protective potential of M. oleifera leaf extract against CP-induced ovarian toxicity, likely mediated by the synergistic antioxidant, anti-inflammatory, and organ-protective properties of its bioactive components.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    cyclophosphamide
    11d
    Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL. (PubMed, Blood)
    This study reports outcomes of PLAT-02, a phase 2 trial of SCRI-CAR19, a second-generation CAR T-cell product with FMC63 scFv and 41BB costimulation, in pediatric and young adult patients with B-cell acute lymphoblastic leukemia; and PLAT-03, a companion study evaluating exogenous CD19 antigen stimulation with serial infusions of T cells expressing truncated CD19, T-cell antigen presenting cells (T-APCs). The efficacy cohort of PLAT-02 (n=72 patients, median age 12.5 years) received fludarabine/cyclophosphamide lymphodepletion followed by a dose of 1X106 CAR+ T cells/kg...Further exploration of serial artificial CD19 antigen exposure is warranted based on these pilot results. PLAT-02 (NCT02028455) and PLAT-03 (NCT03186118).
    Journal
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • SCRI-CAR19
    12d
    CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Mar 2032 --> Sep 2032 | Trial primary completion date: Mar 2032 --> Sep 2032
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    12d
    Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma (clinicaltrials.gov)
    P3, N=107, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    ABCG2 (ATP Binding Cassette Subfamily G Member 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)
    12d
    An Exploratory Clinical Study of CD19 BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Jieyang People's Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    12d
    ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=488, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • IGH (Immunoglobulin Heavy Locus) • ETV6 (ETS Variant Transcription Factor 6) • CD4 (CD4 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    12d
    IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 (clinicaltrials.gov)
    P2, N=10, Terminated, University of Southern California | Active, not recruiting --> Terminated; Lack of efficacy
    Trial termination
    |
    cyclophosphamide • citoplurikin (IRX-2) • omeprazole